An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2

Daniele Focosi; Massimo Franchini; Arturo Casadevall; Fabrizio Maggi

doi:10.1016/j.cmi.2024.04.012

An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2

Clin Microbiol Infect. 2024 Apr 24:S1198-743X(24)00207-6. doi: 10.1016/j.cmi.2024.04.012. Online ahead of print.

Authors

Daniele Focosi¹, Massimo Franchini², Arturo Casadevall³, Fabrizio Maggi⁴

Affiliations

¹ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy. Electronic address: daniele.focosi@gmail.com.
² Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
³ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
⁴ Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.

PMID: 38663655
DOI: 10.1016/j.cmi.2024.04.012

Abstract

Background: Anti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.

Objectives: We review here the current pipeline of anti-spike mAb's, discussing in detail the most promising candidates.

Sources: We scanned PubMed, ClinicalTrials.gov and manufacturers' press releases for clinical studies on anti-spike monoclonal antibodies.

Content: We present state-of-art data clinical progress for AstraZeneca's AZD3152, Invivyd's VYD222, Regeneron's REGN-17092 and Aerium Therapeutics' AER-800.

Implications: The anti-spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions.

Keywords: AZD3152; AZD3959; Efficacy; Monoclonal antibodies; REGN1792; SARS-CoV-2; Safety; Spike; VYD222.

Publication types

Review